Griffin, M., Hillmen, P., Szer, J., Weitz, I. C., Roeth, A., Hoechsmann, B., … De Latour, R. P. (2021). Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria. In BRITISH JOURNAL OF HAEMATOLOGY (Vol. 193, pp. 63–65).

Griffin, Morag, Peter Hillmen, Jeffrey Szer, Ilene C. Weitz, Alexander Roeth, Britta Hoechsmann, Jens Panse, et al. “Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria.” In BRITISH JOURNAL OF HAEMATOLOGY, 193:63–65, 2021.

Griffin M, Hillmen P, Szer J, Weitz IC, Roeth A, Hoechsmann B, et al. Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria. In: BRITISH JOURNAL OF HAEMATOLOGY. 2021. p. 63–5.

Griffin, Morag, et al. “Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria.” BRITISH JOURNAL OF HAEMATOLOGY, vol. 193, 2021, pp. 63–65.

Griffin M, Hillmen P, Szer J, Weitz IC, Roeth A, Hoechsmann B, Panse J, Usuki K, Kiladjian J-J, De Castro CM, Nishimori H, Tan L, Hamdani M, Deschatelets P, Francois C, Grossi F, Risitano A, De Latour RP. Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria. BRITISH JOURNAL OF HAEMATOLOGY. 2021. p. 63–65.